ATE240960T1 - Therapeutisch nützliche arylalkylamine von spirofuropyridinen - Google Patents

Therapeutisch nützliche arylalkylamine von spirofuropyridinen

Info

Publication number
ATE240960T1
ATE240960T1 AT99967044T AT99967044T ATE240960T1 AT E240960 T1 ATE240960 T1 AT E240960T1 AT 99967044 T AT99967044 T AT 99967044T AT 99967044 T AT99967044 T AT 99967044T AT E240960 T1 ATE240960 T1 AT E240960T1
Authority
AT
Austria
Prior art keywords
spirofuropyridines
arylalkylamines
therapeutically useful
therapeutically
useful
Prior art date
Application number
AT99967044T
Other languages
English (en)
Inventor
James Loch Iii
George Mullen
Eifion Astrazeneca R Phillips
Drive Innovation
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE240960T1 publication Critical patent/ATE240960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT99967044T 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen ATE240960T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds
PCT/SE1999/002478 WO2000042044A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy

Publications (1)

Publication Number Publication Date
ATE240960T1 true ATE240960T1 (de) 2003-06-15

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967044T ATE240960T1 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen

Country Status (34)

Country Link
US (2) US6995167B2 (de)
EP (1) EP1147114B1 (de)
JP (1) JP2002534525A (de)
KR (1) KR100660496B1 (de)
CN (1) CN1132837C (de)
AR (1) AR022283A1 (de)
AT (1) ATE240960T1 (de)
AU (1) AU775433B2 (de)
BR (1) BR9916906A (de)
CA (1) CA2359990A1 (de)
CZ (1) CZ20012554A3 (de)
DE (1) DE69908185T2 (de)
DK (1) DK1147114T3 (de)
EE (1) EE04528B1 (de)
ES (1) ES2200590T3 (de)
HK (1) HK1040517B (de)
HU (1) HUP0200513A3 (de)
ID (1) ID30034A (de)
IL (1) IL144266A0 (de)
IS (1) IS6000A (de)
MY (1) MY118109A (de)
NO (1) NO20013478L (de)
NZ (1) NZ512733A (de)
PT (1) PT1147114E (de)
RU (1) RU2233282C2 (de)
SA (1) SA00200987B1 (de)
SE (1) SE9900100D0 (de)
SI (1) SI1147114T1 (de)
SK (1) SK9932001A3 (de)
TR (1) TR200102042T2 (de)
TW (2) TW200413387A (de)
UA (1) UA71598C2 (de)
WO (1) WO2000042044A1 (de)
ZA (1) ZA200105527B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
KR20040003021A (ko) * 2001-06-01 2004-01-07 아스트라제네카 아베 치료에 유용한 니코틴성 아세틸콜린 수용체에 대한 신규리간드
EP1432707B1 (de) * 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
NZ535978A (en) * 2002-04-18 2007-10-26 Astrazeneca Ab Novel spiroazabicyclic heterocyclic amines useful as nicotinic acetylcholine receptor agonists
ATE484508T1 (de) * 2002-04-18 2010-10-15 Astrazeneca Ab Furylverbindungen
US7417050B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Heterocyclic compounds
WO2004019943A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
ES2462545T3 (es) * 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CA2512765A1 (en) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation Therapeutic agent for schizophrenia
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
BRPI0415546A (pt) * 2003-10-21 2006-12-26 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
ME01516B (me) 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
CA2894860C (en) 2008-11-19 2018-11-06 Gerhard Koenig Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
EP3666272A1 (de) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Verwendung von encenicline bei der behandlung von kognitiver behinderung, alzheimer-krankheit, speicherdefizit
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CN105189482A (zh) 2013-02-07 2015-12-23 武田药品工业株式会社 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
US10208016B2 (en) 2013-06-21 2019-02-19 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122353T1 (de) * 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
SU1540240A1 (ru) * 1988-05-16 1995-09-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 5-ЗАМЕЩЕННЫЕ 1-АМИНО -8,9-ДИГИДРО -8,8-ДИМЕТИЛ-3, 6Н- ПИРАЗОЛО [3,4-B] ПИРАНО[[4′,3′-d]] ПИРИДИНА ИЛИ ИХ ГИДРОХЛОРИДЫ, ОБЛАДАЮЩИЕ ПРОТИВОСУДОРОЖНОЙ АКТИВНОСТЬЮ
PT777671E (pt) * 1994-08-24 2000-08-31 Astrazeneca Ab Compostos espiro-azabiciclicos uteis em terapia
DK0842178T3 (da) * 1995-07-28 2001-08-06 Abbott Lab Furopyridin, thienopyridin, pyrrolopyridin og beslægtede pyrimidin-, pyridazin- og triazinforbindelser, som er nyttige til regulering af kemisk synaptisk transmission
US6156783A (en) 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
CA2359990A1 (en) 2000-07-20
IS6000A (is) 2001-07-12
DE69908185T2 (de) 2004-06-03
ES2200590T3 (es) 2004-03-01
HUP0200513A3 (en) 2004-07-28
DK1147114T3 (da) 2003-09-15
NO20013478D0 (no) 2001-07-13
TR200102042T2 (tr) 2002-05-21
HK1040517B (en) 2003-09-05
US6995167B2 (en) 2006-02-07
US20050250802A1 (en) 2005-11-10
SE9900100D0 (sv) 1999-01-15
US7196096B2 (en) 2007-03-27
EE04528B1 (et) 2005-08-15
ZA200105527B (en) 2002-10-04
TW200413387A (en) 2004-08-01
CN1337964A (zh) 2002-02-27
BR9916906A (pt) 2001-10-30
HK1040517A1 (en) 2002-06-14
CN1132837C (zh) 2003-12-31
DE69908185D1 (de) 2003-06-26
NO20013478L (no) 2001-09-14
AU775433B2 (en) 2004-07-29
RU2233282C2 (ru) 2004-07-27
IL144266A0 (en) 2002-05-23
SI1147114T1 (en) 2003-12-31
UA71598C2 (en) 2004-12-15
EP1147114A1 (de) 2001-10-24
TWI227237B (en) 2005-02-01
EE200100370A (et) 2002-10-15
AR022283A1 (es) 2002-09-04
SK9932001A3 (en) 2002-04-04
JP2002534525A (ja) 2002-10-15
ID30034A (id) 2001-11-01
KR20010086167A (ko) 2001-09-08
US20030149065A1 (en) 2003-08-07
EP1147114B1 (de) 2003-05-21
CZ20012554A3 (cs) 2002-01-16
MY118109A (en) 2004-08-30
KR100660496B1 (ko) 2006-12-22
NZ512733A (en) 2003-08-29
PT1147114E (pt) 2003-10-31
SA00200987B1 (ar) 2006-11-07
AU2334300A (en) 2000-08-01
HUP0200513A2 (en) 2002-06-29
WO2000042044A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
DE69908185D1 (de) Therapeutisch nützliche arylalkylamine von spirofuropyridinen
DK1637127T3 (da) Terapeutisk mikroskum
NO20035529D0 (no) Sementeringshode
DE69926752D1 (de) Therapeutisch wirksame biaryl-derivate
FR2856445B1 (fr) Joint homocinetique tripode
IT1313881B1 (it) Giunto omocinetico
ATE512949T1 (de) Reninhemmer
PT1235558E (pt) Agentes terapeuticos
ATE363478T1 (de) Renin inhibitoren
ID24409A (id) Struktur suatu jembatan gitar
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
DE60030723D1 (de) Substanziell kristalline form von melagatran
ATE254929T1 (de) Oralverabreichbare lösung von prucaloprid
ID27403A (id) Struktur lantai-injak skuter
EP1197556A4 (de) NüTZLICHE POLYPEPTIDE
ID28397A (id) Struktur alat penstabil
DE60026931D1 (de) Ausrichtung von Ausdrucken
DE60031450D1 (de) Polymorph v von torasemid
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
EE200100381A (et) Morfolinobensamiidi uued soolad
DE60004414D1 (de) Kreisel
NO20016301D0 (no) Terapeutiske midler
ID30381A (id) Penggunaan arilalkanoilpiridazina
EE200200053A (et) Isoretinoiini valmistamise protsess
DE50015603D1 (de) Strukturausrichtung von membranen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1147114

Country of ref document: EP

REN Ceased due to non-payment of the annual fee